Breaking the therapeutic ceiling in drug development in ulcerative colitis

Article describes the current “therapeutic ceiling” in ulcerative colitis, noting that remission rates even with new biologics is modest at 20-30%. This review provides possible explanations for the shortcomings of current strategies.

Lancet Gastroenterology and Hepatology